PL2017278T3 - Pochodne dihydropirazolopirymidynonu - Google Patents

Pochodne dihydropirazolopirymidynonu

Info

Publication number: PL2017278T3
Authority: PL; Poland
Prior art keywords: dihydropyrazolopyrimidinone; derivative; dihydropyrazolopyrimidinone derivative
Prior art date: 2006-04-27

Application number

PL07742851T

Other languages

English (en)

Inventor

Toshihiro Sakamoto

Satoshi Sunami

Fuyuki Yamamoto

Kenji Niiyama

Makoto Bamba

Keiji Takahashi

Hidetomo Furuyama

Yasuhiro Goto

Takeshi Sagara

Sachie Otsuki

Toshihide Nishibata

Takashi Yoshizumi

Hiroshi Hirai

Original Assignee

Msd Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-27

Filing date

2007-04-25

Publication date

2017-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2017278(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-04-25 Application filed by Msd Kk filed Critical Msd Kk

2017-10-31 Publication of PL2017278T3 publication Critical patent/PL2017278T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

PL07742851T 2006-04-27 2007-04-25 Pochodne dihydropirazolopirymidynonu PL2017278T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2006124208		2006-04-27
PCT/JP2007/059416 WO2007126128A1 (ja)	2006-04-27	2007-04-25	ジヒドロピラゾロピリミジノン誘導体
EP07742851.4A EP2017278B1 (en)	2006-04-27	2007-04-25	Dihydropyrazolopyrimidinone derivative

Publications (1)

Publication Number	Publication Date
PL2017278T3 true PL2017278T3 (pl)	2017-10-31

Family

ID=38655640

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL07742851T PL2017278T3 (pl)	2006-04-27	2007-04-25	Pochodne dihydropirazolopirymidynonu
PL07742843T PL2016080T3 (pl)	2006-04-27	2007-04-25	Pochodne dihydropirazolopirymidynonu

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL07742843T PL2016080T3 (pl)	2006-04-27	2007-04-25	Pochodne dihydropirazolopirymidynonu

Country Status (38)

Country	Link
US (4)	US7834019B2 (pl)
EP (2)	EP2016080B1 (pl)
JP (2)	JP4513919B2 (pl)
KR (1)	KR101409161B1 (pl)
CN (1)	CN101432284B (pl)
AR (1)	AR060635A1 (pl)
AT (1)	ATE475662T1 (pl)
AU (1)	AU2007244185B2 (pl)
BR (1)	BRPI0710081A2 (pl)
CA (1)	CA2650119C (pl)
CR (1)	CR10359A (pl)
CY (2)	CY1111069T1 (pl)
DE (1)	DE602007008085D1 (pl)
DK (2)	DK2017278T3 (pl)
DO (1)	DOP2007000084A (pl)
EC (1)	ECSP088812A (pl)
ES (2)	ES2348751T3 (pl)
GT (1)	GT200800211A (pl)
HN (1)	HN2008001532A (pl)
HR (2)	HRP20161763T1 (pl)
HU (1)	HUE032987T2 (pl)
IL (1)	IL194367A (pl)
LT (1)	LT2017278T (pl)
MA (1)	MA30428B1 (pl)
MX (1)	MX2008013063A (pl)
MY (1)	MY145408A (pl)
NO (1)	NO341617B1 (pl)
NZ (1)	NZ571196A (pl)
PE (1)	PE20080695A1 (pl)
PL (2)	PL2017278T3 (pl)
PT (2)	PT2016080E (pl)
RU (1)	RU2437885C2 (pl)
SI (2)	SI2016080T1 (pl)
SV (1)	SV2009003060A (pl)
TW (1)	TWI409262B (pl)
UA (1)	UA96152C2 (pl)
WO (2)	WO2007126128A1 (pl)
ZA (1)	ZA200807748B (pl)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR060635A1 (es) *	2006-04-27	2008-07-02	Banyu Pharma Co Ltd	Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
WO2008133866A1 (en) *	2007-04-25	2008-11-06	Merck & Co., Inc.	Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
WO2008141385A1 (en) *	2007-05-21	2008-11-27	Biota Scientific Management Pty Ltd	Viral polymerase inhibitors
AU2008315048A1 (en) *	2007-10-23	2009-04-30	Msd K.K.	Pyridone-substituted-dihydropyrazolopyrimidinone derivative
ES2430053T3 (es)	2008-06-12	2013-11-18	Merck Sharp & Dohme Corp.	Procedimiento para producir derivados de bicicloanilina
EP2376494A4 (en) *	2008-12-12	2012-07-11	Msd Kk	DIHYDROPYRIMIDOPYRIMIDINDERIVATE
WO2010076887A1 (en) *	2009-01-05	2010-07-08	Banyu Pharmaceutical Co.,Ltd.	Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
EP2401281A4 (en)	2009-02-25	2012-08-15	Msd Kk	PYRIMIDINPYRIMIDOINDAZOLDERIVAT
EP2473633A4 (en) *	2009-09-02	2013-03-06	Msd Kk	USE OF ONE OR MORE BIOMARKERS TO IDENTIFY A WEE1 DISEASED PATIENT AND PROCEDURE FOR TREATING CANCER MEDIATED BY DYSFUNCTIONAL OR ABERRANT P53 BY ADMINISTERING A WEE1 HEMMER
HRP20140821T1 (hr)	2009-09-15	2014-10-10	Merck Sharp & Dohme Corp.	Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona
WO2012074754A1 (en)	2010-11-16	2012-06-07	Array Biopharma Inc.	Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
EP3483141B1 (en) *	2011-04-27	2023-07-19	Zeon Corporation	Polymerizable compound, polymerizable composition, polymer, and optically anisotropic material
WO2013013031A1 (en) *	2011-07-19	2013-01-24	Abbvie Inc.	Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
US9345705B2 (en)	2011-09-15	2016-05-24	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
EP2776434A1 (en) *	2011-10-20	2014-09-17	Abbvie Inc.	Pyridopyrimidinone inhibitors of kinases
JP2015511245A (ja) *	2012-02-23	2015-04-16	アッヴィ・インコーポレイテッド	ピリドピリミジノン系キナーゼ阻害薬
WO2014062454A1 (en) *	2012-10-15	2014-04-24	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
EP2925888B1 (en) *	2012-11-28	2017-10-25	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
EA201591931A1 (ru)	2013-04-09	2016-05-31	Ликсте Байотекнолоджи, Инк.	Композиции оксабициклогептанов и оксабициклогептенов
GB201306610D0 (en) *	2013-04-11	2013-05-29	Almac Discovery Ltd	Pharmaceutical compounds
GB201322602D0 (en)	2013-12-19	2014-02-05	Almac Discovery Ltd	Pharmaceutical compounds
EP3235505B1 (en) *	2014-12-17	2020-05-06	Delta-Fly Pharma, Inc.	Pharmaceutical composition for treatment or palliation of elderly or end-stage cancer patient
UY36629A (es)	2015-04-17	2016-11-30	Abbvie Inc	Indazolonas como moduladores de la señalización de tnf
EP3288939A1 (en)	2015-04-17	2018-03-07	AbbVie Inc.	Tricyclic modulators of tnf signaling
UY36628A (es)	2015-04-17	2016-11-30	Abbvie Inc	Indazolonas como moduladores de la señalización de tnf
JP6141568B1 (ja) *	2015-09-01	2017-06-07	大鵬薬品工業株式会社	新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
CN105130986B (zh) *	2015-09-30	2017-07-18	广州科擎新药开发有限公司	嘧啶或吡啶并吡啶酮类化合物及其应用
JP6692423B2 (ja) *	2015-11-01	2020-05-13	ザリージェンツオブザユニヴァーシティオブコロラド，アボディコーポレイト	Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
GB201612092D0 (en) *	2016-07-12	2016-08-24	Almac Discovery Ltd	Pharmaceutical compounds
UA123287C2 (uk)	2016-09-15	2021-03-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Гетероарилкарбоксамідні сполуки як інгібітори ripk2
CN106719769A (zh) *	2016-11-28	2017-05-31	山东农业大学	一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
ES2970913T3 (es)	2016-12-08	2024-05-31	Lixte Biotechnology Inc	Oxabicicloheptanos para modulación de la respuesta inmunitaria
US10954253B2 (en)	2017-01-23	2021-03-23	Shijiazhuang Sagacity New Drug Development Co., Ltd.	1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor
GB201703881D0 (en) *	2017-03-10	2017-04-26	Almac Discovery Ltd	Pharmaceutical compounds
EP3604306B1 (en)	2017-03-23	2022-10-26	Shanghai de Novo Pharmatech Co., Ltd.	Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof
KR20190130621A (ko)	2017-03-31	2019-11-22	시애틀 지네틱스, 인크.	Chk1 저해제와 wee1 저해제의 조합물
EP3661918B1 (en)	2017-08-01	2024-05-08	Recurium IP Holdings, LLC	1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one analogs
CN109422754A (zh) *	2017-08-24	2019-03-05	上海迪诺医药科技有限公司	吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
AU2018347307A1 (en)	2017-10-09	2020-04-23	Nuvation Bio Inc.	Heterocyclic compounds and uses thereof
US11299493B2 (en)	2017-10-09	2022-04-12	Nuvation Bio Inc.	Heterocyclic compounds and uses thereof
WO2019085933A1 (zh)	2017-11-01	2019-05-09	南京明德新药研发股份有限公司	作为Wee1抑制剂的大环类化合物及其应用
WO2019096322A1 (zh) *	2017-11-20	2019-05-23	上海医药集团股份有限公司	一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019134539A1 (zh) *	2018-01-05	2019-07-11	四川科伦博泰生物医药股份有限公司	二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en)	2018-02-23	2022-10-25	Newave Pharmaceutical Inc.	Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
AU2019227823B2 (en) *	2018-02-28	2024-12-12	The Regents Of The University Of Colorado, A Body Corporate	WEE1 kinase inhibitors and methods of treating cancer using the same
PL3762385T3 (pl) *	2018-03-09	2025-06-23	Recurium Ip Holdings, Llc	Podstawione 1,2-dihydro-3h-pirazolo[3,4-d]pirymidyn-3-ony
CN108653282B (zh) *	2018-06-28	2020-08-14	中国科学院昆明植物研究所	苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
WO2020083404A1 (zh)	2018-10-26	2020-04-30	南京明德新药研发有限公司	作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
CN111662283B (zh) *	2019-03-07	2021-11-16	湖南化工研究院有限公司	咪唑并吡啶类化合物及其中间体、制备方法与应用
US20220194960A1 (en) *	2019-03-22	2022-06-23	Shouyao Holdings (beijing) Co., Ltd.	Wee1 inhibitor and preparation and use thereof
EP3952875A4 (en) *	2019-04-09	2022-12-28	Nuvation Bio Inc.	HETEROCYCLIC COMPOUNDS AND USES THEREOF
MX2021012418A (es)	2019-04-09	2021-11-12	Nuvation Bio Inc	Compuestos heterociclicos y sus usos.
WO2020210320A1 (en) *	2019-04-11	2020-10-15	Recurium Ip Holdings, Llc	Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
HUE068061T2 (hu)	2019-04-30	2024-12-28	Wuxi Biocity Biopharmaceutics Co Ltd	WEE1 inhibitor vegyület kristályos formája és felhasználása
CN112142748B (zh)	2019-06-28	2023-07-04	上海医药集团股份有限公司	一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2020259703A1 (zh) *	2019-06-28	2020-12-30	上海医药集团股份有限公司	一种吡唑酮并嘧啶类化合物、其制备方法及应用
US20220387468A1 (en)	2019-10-25	2022-12-08	Astrazeneca Ab	Methods of treating cancer
MX2022007628A (es) *	2019-12-20	2022-08-25	Recurium Ip Holdings Llc	Combinaciones.
CN113387962A (zh) *	2020-03-12	2021-09-14	上海迪诺医药科技有限公司	吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
AU2021290701A1 (en) *	2020-06-17	2023-02-02	Wigen Biomedicine Technology (shanghai) Co., Ltd.	Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
KR102549484B1 (ko) *	2020-12-08	2023-06-29	한국화학연구원	피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
WO2022171128A1 (zh) *	2021-02-09	2022-08-18	微境生物医药科技(上海)有限公司	作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171088A1 (zh) *	2021-02-09	2022-08-18	微境生物医药科技(上海)有限公司	吡唑并[3,4-d]嘧啶-3-酮衍生物
CN116848117A (zh) *	2021-02-09	2023-10-03	微境生物医药科技(上海)有限公司	作为Wee-1抑制剂的稠环化合物
CN115197221B (zh) *	2021-04-02	2024-05-24	轩竹(北京)医药科技有限公司	二氢吡唑并嘧啶酮类大环衍生物及其用途
KR20240004584A (ko)	2021-04-29	2024-01-11	노파르티스 아게	탈유비퀴티나아제-표적화 키메라 및 관련된 방법
BR112023022236A2 (pt)	2021-04-30	2024-02-06	Wigen Biomedicine Tech Shanghai Co Ltd	Composto de fórmula geral (1) ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato; composição farmacêutica; e; uso do composto ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato
CN115403582A (zh)	2021-05-28	2022-11-29	江苏天士力帝益药业有限公司	Wee1抑制剂及其用途
WO2023041066A1 (zh) *	2021-09-18	2023-03-23	优领医药科技(香港)有限公司	含嘧啶并二氢吡唑啉酮类衍生物、其药学上可接受的盐及其制备方法和应用
CN113735863A (zh) *	2021-09-29	2021-12-03	武汉九州钰民医药科技有限公司	Wee1抑制剂adavosertib的制备工艺
CN113880844B (zh) *	2021-09-29	2023-02-14	武汉九州钰民医药科技有限公司	Wee1蛋白激酶抑制剂adavosertib的化学合成方法
TW202322812A (zh) *	2021-11-01	2023-06-16	大陸商正大天晴藥業集團股份有限公司	吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
CN116462687B (zh) *	2022-01-18	2025-01-07	江苏天士力帝益药业有限公司	Wee1抑制剂及其制备和用途
CN116836184B (zh) *	2022-03-25	2025-07-25	药雅科技(上海)有限公司	Wee1激酶抑制剂的制备及其应用
CN117402162A (zh)	2022-07-13	2024-01-16	江苏天士力帝益药业有限公司	Wee1抑制剂及其制备和用途
CN115073460B (zh) *	2022-07-13	2023-07-25	苏州施安鼎泰生物医药技术有限公司	一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
WO2024012549A1 (zh) *	2022-07-15	2024-01-18	映恩生物制药（苏州）有限公司	一种嘧啶并五元杂环化合物、其制备方法和用途
CN119798282A (zh) *	2023-10-11	2025-04-11	智擎生技制药股份有限公司	基于稠合吡啶环的Myt1抑制剂
TW202519226A (zh)	2023-11-08	2025-05-16	美商艾克塞里克斯公司	使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
OA07174A (fr)	1981-08-24	1984-04-30	May & Baker Ltd	Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja)	1983-07-14	1985-01-31	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) *	1987-08-26	1997-07-09	三井製薬工業株式会社	ピリミジン類及びその薬学的に許容される塩類
US5223608A (en)	1987-08-28	1993-06-29	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
HUT70024A (en)	1990-09-28	1995-09-28	Smithkline Beecham Corp	Process for preparing water soluble camptothecin analogs
US5162532A (en)	1990-12-20	1992-11-10	North Carolina State University	Intermediates and method of making camptothecin and camptothecin analogs
US5200524A (en)	1990-12-20	1993-04-06	North Carolina State University	Camptothecin intermediates and method of making same
US5243050A (en)	1990-12-20	1993-09-07	North Carolina State University	Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en)	1990-12-20	1993-03-02	North Carolina State University	Camptothecin intermediate and method of making camptothecin intermediates
US5247089A (en)	1990-12-20	1993-09-21	North Carolina State University	Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
AU687727B2 (en)	1992-10-28	1998-03-05	Genentech Inc.	Vascular endothelial cell growth factor antagonists
JP3025602B2 (ja)	1993-05-21	2000-03-27	デビオファームエス．アー．	光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
JPH11507535A (ja)	1995-06-07	1999-07-06	イムクローンシステムズインコーポレイテッド	腫瘍の成長を抑制する抗体および抗体フラグメント類
JP3154399B2 (ja)	1996-07-04	2001-04-09	デビオファームエス．アー．	白金化合物の製造方法
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv)	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinoline compounds
MXPA04010617A (es)	2002-04-26	2004-12-13	Warner Lambert Co	Inhibidores de quinasa de puntos de control (wee1 y chk1).
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA05007503A (es) *	2003-01-17	2005-09-21	Warner Lambert Co	Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
WO2004072063A1 (en) *	2003-02-07	2004-08-26	Vertex Pharmaceuticals Incorporated	Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
US7320992B2 (en) *	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en)	2004-05-03	2005-11-10	Pfizer Inc	Inhibitors of checkpoint kinases (Wee1 and Chk1)
DK1775298T3 (da)	2004-07-01	2013-05-21	Daiichi Sankyo Co Ltd	Thienopyrazolderivat med PDE7-inhibitorisk aktivitet
US7947695B2 (en) *	2005-01-14	2011-05-24	Janssen Pharmaceutica Nv	5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en)	2005-02-24	2006-08-31	Kemia, Inc.	Modulators of gsk-3 activity
AR060635A1 (es)	2006-04-27	2008-07-02	Banyu Pharma Co Ltd	Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer

2007
- 2007-04-24 AR ARP070101763A patent/AR060635A1/es active IP Right Grant
- 2007-04-24 PE PE2007000511A patent/PE20080695A1/es active IP Right Grant
- 2007-04-25 UA UAA200813667A patent/UA96152C2/ru unknown
- 2007-04-25 AT AT07742843T patent/ATE475662T1/de active
- 2007-04-25 EP EP07742843A patent/EP2016080B1/en active Active
- 2007-04-25 WO PCT/JP2007/059416 patent/WO2007126128A1/ja not_active Ceased
- 2007-04-25 PL PL07742851T patent/PL2017278T3/pl unknown
- 2007-04-25 AU AU2007244185A patent/AU2007244185B2/en not_active Ceased
- 2007-04-25 DK DK07742851.4T patent/DK2017278T3/en active
- 2007-04-25 RU RU2008146759/04A patent/RU2437885C2/ru active
- 2007-04-25 PT PT07742843T patent/PT2016080E/pt unknown
- 2007-04-25 US US11/789,548 patent/US7834019B2/en active Active
- 2007-04-25 MX MX2008013063A patent/MX2008013063A/es active IP Right Grant
- 2007-04-25 SI SI200730373T patent/SI2016080T1/sl unknown
- 2007-04-25 KR KR1020087026239A patent/KR101409161B1/ko active Active
- 2007-04-25 US US12/226,707 patent/US7935708B2/en active Active
- 2007-04-25 LT LTEP07742851.4T patent/LT2017278T/lt unknown
- 2007-04-25 WO PCT/JP2007/059408 patent/WO2007126122A1/en not_active Ceased
- 2007-04-25 EP EP07742851.4A patent/EP2017278B1/en active Active
- 2007-04-25 PL PL07742843T patent/PL2016080T3/pl unknown
- 2007-04-25 SI SI200731875A patent/SI2017278T1/sl unknown
- 2007-04-25 ES ES07742843T patent/ES2348751T3/es active Active
- 2007-04-25 HU HUE07742851A patent/HUE032987T2/en unknown
- 2007-04-25 DK DK07742843.1T patent/DK2016080T3/da active
- 2007-04-25 NZ NZ571196A patent/NZ571196A/en not_active IP Right Cessation
- 2007-04-25 JP JP2008513330A patent/JP4513919B2/ja active Active
- 2007-04-25 PT PT77428514T patent/PT2017278T/pt unknown
- 2007-04-25 DE DE602007008085T patent/DE602007008085D1/de active Active
- 2007-04-25 CN CN2007800150647A patent/CN101432284B/zh active Active
- 2007-04-25 CA CA2650119A patent/CA2650119C/en active Active
- 2007-04-25 HR HRP20161763TT patent/HRP20161763T1/hr unknown
- 2007-04-25 HR HR20100563T patent/HRP20100563T1/hr unknown
- 2007-04-25 BR BRPI0710081-7A patent/BRPI0710081A2/pt not_active Application Discontinuation
- 2007-04-25 ES ES07742851.4T patent/ES2609087T3/es active Active
- 2007-04-27 DO DO2007000084A patent/DOP2007000084A/es unknown
- 2007-04-27 TW TW096114902A patent/TWI409262B/zh not_active IP Right Cessation
2008
- 2008-09-09 ZA ZA200807748A patent/ZA200807748B/xx unknown
- 2008-09-18 MY MYPI20083651A patent/MY145408A/en unknown
- 2008-09-25 IL IL194367A patent/IL194367A/en active IP Right Grant
- 2008-10-09 EC EC2008008812A patent/ECSP088812A/es unknown
- 2008-10-10 CR CR10359A patent/CR10359A/es unknown
- 2008-10-10 HN HN2008001532A patent/HN2008001532A/es unknown
- 2008-10-10 SV SV2008003060A patent/SV2009003060A/es unknown
- 2008-10-10 GT GT200800211A patent/GT200800211A/es unknown
- 2008-11-24 MA MA31411A patent/MA30428B1/fr unknown
- 2008-11-26 NO NO20084968A patent/NO341617B1/no unknown
2010
- 2010-02-08 JP JP2010025458A patent/JP5167291B2/ja not_active Expired - Fee Related
- 2010-10-27 CY CY20101100973T patent/CY1111069T1/el unknown
2011
- 2011-03-22 US US13/053,798 patent/US8791125B2/en active Active
2014
- 2014-06-24 US US14/312,982 patent/US20140303178A1/en not_active Abandoned
2017
- 2017-01-27 CY CY20171100129T patent/CY1118526T1/el unknown

Also Published As

Publication number	Publication date
NZ571196A (en)	2011-03-31
ZA200807748B (en)	2009-10-28
MY145408A (en)	2012-02-15
KR101409161B1 (ko)	2014-06-19
MA30428B1 (fr)	2009-05-04
RU2008146759A (ru)	2010-06-10
US20140303178A1 (en)	2014-10-09
TWI409262B (zh)	2013-09-21
HUE032987T2 (en)	2017-11-28
SV2009003060A (es)	2009-04-28
HK1132498A1 (en)	2010-02-26
JP5167291B2 (ja)	2013-03-21
IL194367A (en)	2014-12-31
PT2016080E (pt)	2010-10-14
CN101432284B (zh)	2012-08-15
IL194367A0 (en)	2009-08-03
EP2017278B1 (en)	2016-11-02
HN2008001532A (es)	2009-06-10
AU2007244185A1 (en)	2007-11-08
KR20090017491A (ko)	2009-02-18
US20070254892A1 (en)	2007-11-01
CA2650119A1 (en)	2007-11-08
DE602007008085D1 (en)	2010-09-09
WO2007126128A1 (ja)	2007-11-08
EP2017278A1 (en)	2009-01-21
CR10359A (es)	2009-02-19
HRP20161763T1 (hr)	2017-02-24
AU2007244185B2 (en)	2012-10-04
RU2437885C2 (ru)	2011-12-27
BRPI0710081A2 (pt)	2011-08-02
ES2348751T3 (es)	2010-12-13
DOP2007000084A (es)	2007-12-31
EP2017278A4 (en)	2009-04-22
ECSP088812A (es)	2008-11-27
PL2016080T3 (pl)	2011-03-31
PT2017278T (pt)	2017-01-03
ATE475662T1 (de)	2010-08-15
WO2007126122A1 (en)	2007-11-08
US20100063024A1 (en)	2010-03-11
JPWO2007126128A1 (ja)	2009-09-17
EP2016080B1 (en)	2010-07-28
TW200811176A (en)	2008-03-01
PE20080695A1 (es)	2008-06-28
EP2016080A1 (en)	2009-01-21
AR060635A1 (es)	2008-07-02
US8791125B2 (en)	2014-07-29
US7834019B2 (en)	2010-11-16
EP2016080A4 (en)	2009-05-13
DK2017278T3 (en)	2017-02-13
CY1111069T1 (el)	2012-05-23
LT2017278T (lt)	2017-01-25
NO20084968L (no)	2008-11-26
CY1118526T1 (el)	2017-07-12
NO341617B1 (no)	2017-12-11
JP4513919B2 (ja)	2010-07-28
SI2017278T1 (sl)	2017-05-31
DK2016080T3 (da)	2010-11-22
UA96152C2 (en)	2011-10-10
HRP20100563T1 (hr)	2010-11-30
CN101432284A (zh)	2009-05-13
US20110189130A1 (en)	2011-08-04
MX2008013063A (es)	2008-12-16
CA2650119C (en)	2017-03-14
US7935708B2 (en)	2011-05-03
JP2010132689A (ja)	2010-06-17
SI2016080T1 (sl)	2011-03-31
GT200800211A (es)	2009-04-07
ES2609087T3 (es)	2017-04-18

Publication	Publication Date	Title
HUS2400041I1 (hu)	2024-12-28	4-Pirimidin-szulfamid-származék
SI2017278T1 (sl)	2017-05-31	Derivat dihidropirazolopirimidinona
EP2009005A4 (en)	2010-06-02	AZOLECARBOXAMIDE DERIVATIVE
ZA200901336B (en)	2010-06-30	Pyridizinone derivatives
IL193641A0 (en)	2009-05-04	Spiroindolinone derivatives
IL195013A0 (en)	2009-08-03	Pyridopyrimidinone derivatives
IL198319A0 (en)	2010-02-17	Spiroindolinone derivatives
ZA200908298B (en)	2010-08-25	Bicycloaniline derivative
IL195422A0 (en)	2009-08-03	2-pyrazinecarboxamide derivatives
IL192401A0 (en)	2008-12-29	Indol-3-yl-carbonyl-spiro-piperidine derivatives
IL198059A0 (en)	2009-12-24	2-aminocarbonyl-pyridine derivatives
IL196364A0 (en)	2009-09-22	Aminoindazolylurea derivatives
IL193211A0 (en)	2009-02-11	Indazole-heteroaryl derivatives
IL198645A0 (en)	2010-02-17	5-hydroxymethyl-oxazolidin-2-one derivatives
IL192799A0 (en)	2009-02-11	Substituted 4-phenylpiperidines
IL197152A0 (en)	2009-11-18	5-phenyl-nicotinamide derivatives
EP2163554A4 (en)	2010-12-15	PYRIMIDODIAZEPINONE DERIVATIVE
ZA200807460B (en)	2010-02-24	Spiroindolinone derivatives
IL197239A0 (en)	2009-12-24	Phenyloxyaniline derivatives
IL198469A0 (en)	2010-02-17	Substituted 4-imidazoles
EP2228362A4 (en)	2011-10-12	4-HYDROXYPHENYLALKYLAMINE DERIVATIVE
GB0614154D0 (en)	2006-08-23	Novel Pyriazine Derivatives
ZA200903280B (en)	2010-07-28	2-aminocarbonyl-pyridine derivatives
GB0610019D0 (en)	2006-06-28	Benzotriazepinone derivatives
IL198973A0 (en)	2010-02-17	Sulfamatobenzothiophene derivatives